Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Complementary and Alternative Medicine

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Screening North American plant extracts in vitro against Trypanosoma brucei for discovery of new antitrypanosomal drug leads

BMC Complementary and Alternative MedicineBMC series – open, inclusive and trusted201616:131

https://doi.org/10.1186/s12906-016-1122-0

Received: 24 November 2015

Accepted: 13 May 2016

Published: 18 May 2016

Abstract

Background

Human African Trypanosomiasis (HAT) is a protozoan parasitic disease caused by Trypanosoma brucei. The disease is endemic in regions of sub-Saharan Africa, covering 36 countries and more than 60 million people at the risk. Only few drugs are available for the treatment of HAT. Current drugs suffer from severe toxicities and require intramuscular or intravenous administrations. The situation is further aggravated due to the emergence of drug resistance. There is an urgent need of new drugs that are effective orally against both stages of HAT. Natural products offer an unmatched source for bioactive molecules with new chemotypes.

Methods

The extracts prepared from 522 plants collected from various parts of the North America were screened in vitro against blood stage trypamastigote forms of T. brucei. Active extracts were further screened at concentrations ranging from 10 to 0.4 μg/mL. Active extracts were also investigated for toxicity in Differentiated THP1 cells at 10 μg/mL concentration. The results were computed for dose–response analysis and determination of IC50/IC90 values.

Results

A significant number (150) of extracts showed >90 % inhibition of growth of trypomastigote blood forms of T. brucei in primary screening at 20 μg/mL concentration. The active extracts were further investigated for dose–response inhibition of T. brucei growth. The antitrypansomal activity of 125 plant extracts was confirmed with IC50 < 10 μg/mL. None of these active extracts showed toxicity against differentiated THP1 cells. Eight plants extracts namely, Alnus rubra, Hoita macrostachya, Sabal minor, Syzygium aqueum, Hamamelis virginiana, Coccoloba pubescens, Rhus integrifolia and Nuphar luteum were identified as highly potent antitrypanosomal extracts with IC50 values <1 μg/mL.

Conclusions

Limited phytochemical and pharmacological reports are available for the lead plant extracts with potent antitrypanosomal activity. Follow up evaluation of these plant extracts is likely to yield new antitrypanosomal drug-leads or alternate medicines for treatment of HAT.

Keywords

Trypanosoma brucei Natural productsHuman African trypanosomiasisNorth American plants

Background

Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by infection with Trypanosoma brucei. HAT is almost always fatal, if untreated or inadequately treated, and is a substantial cause of both mortality and morbidity in affected regions. Infection with T. brucei also has a substantial effect on livestock production [1]. The human disease occurs in two forms, depending on the subspecies of the trypanosome involved. Trypanosoma brucei gambiense causes a chronic infection that may persist for months or even years without major signs or symptoms of the disease. Trypanosoma brucei rhodesiense causes an acute infection [2], where signs and symptoms of the disease are observed a few weeks after the infective bite. The acute form develops rapidly, soon invading the central nervous system [3]. Currently, only four drugs are registered for the treatment of the HAT, which were developed several years ago. All drugs are toxic and require cumbersome treatment schedules. Pentamidine is used to treat the first stage of T. brucei gambiense infection [4]. Suramin is used to treat the first stage of T. brucei rhodesiense infection [4]. Intravenous melarsoprol is used in the second stage of both forms of the disease [5]. On average, 5 % of patients treated with melarsoprol have a fatal serious adverse event [6]. Eflornithine is used in the second stage of T. b. gambiense infection. No new chemical agents have been approved since eflornithine in 1990. A new protocol for the treatment of late-stage T. brucei gambiense that uses the combination nifurtomox/eflornithine (NECT) was recently shown to have better safety and efficacy than eflornithine alone, while being easier to administer [7]. This breakthrough represents the only new therapy for HAT since the approval of eflornithine. Toxicity and suboptimal efficacy of currently available HAT drugs, the growing problem of drug resistance to pentamidine and melarsoprol [8, 9] and severely depleted antitypanosomal drug discovery pipeline necessitate the discovery of new antitrypanosomal drugs with better efficacy and safety profiles. Natural products remain an unmatched source of drugs leads with diverse and novel chemotypes. About 70 % of the currently available drugs have their origin from natural products, mainly from plants. Screening of natural products plant extracts will promise potential for discovery of new drug leads [10]. The North American plants have shown significant medicinal values. However, the plants from this region of the world have not been explored earlier for new antiparasitic and antiprotozoal drug discovery. This study presents the results on screenings of the extracts prepared from the plants collected from this region for discovery of new natural products drug-leads and alternate medicines from traditional natural products sources for treatment of human African trypanosomiasis. Trypansoma brucei brucei strain 427 a non-human sub specie, which has been extensively used for molecular and biochemical investigations on trypanosomes and compounds screening, was employed for the screening [11, 12].

Methods

Plant collection

Botanists at the Missouri Botanical Garden, St. Louis, Missouri (MOBOT) collected the plants the plants from different parts of North America, under a cooperative scientific agreement with the National Center for Natural Products Research. The information on NPID (a unique identification number), sample name, code, genus, species, family, source, common name, plant part, geographical location, collector and collector’s number are given in the supplement Table (Additional file 1: Table S1).

Extraction procedure

Bulk plant samples are dried and frozen in the field and freeze dried at the University of Mississippi before extraction. The freeze-dried plant materials were extracted with Dionex ASE 300. Extraction was done in 95 % ethanol. Each sample was placed in a specific ASE cell and extracted at 1500 psi, at 40 °C for 3 times with 10 min static time/extraction. ASE cells were purged for 120 s. After extraction the extracts were dried and dissolved in DMSO at a concentration of 20 mg/mL.

Culture maintenance

Blood stage forms of Trypanosoma brucei brucei (bloodstream form, Strain 427 obtained from Frederick S. Buckner, Department of Medicine, University of Washington, Seattle, Washington, USA) was grown in IMDM medium supplemented with 10 % fetal bovine serum. The culture was maintained at 37 °C in 5 % CO2 incubator. THP1 cells obtained from ATCC were grown in RPMI 1640 medium supplemented with 10 % fetal bovine serum. The culture was maintained at 37 °C in 5 % CO2 incubator.

Antitrypanosomal assay

A 2 days old culture of T. brucei brucei in the exponential phase was diluted with IMDM to 5000 parasites/mL. Maximum permissible limit of DMSO in the assay was 0.5 %. The assays were set up in clear 96 well microplates. For primary screening (Single concentration of 20 μg/mL in duplicate) extract dilutions (1 mg/mL) were prepared from the stock extracts (20 mg/mL) in IMDM medium. Each well received 4 μL of diluted extract sample and 196 μL of the culture volume (total culture volume 200 μl). The plates were incubated at 37 °C in 5 % CO2 for 48 h. Alamar blue (10 μl) (AbD Serotec, catalog number BUF012B) was added to each well and the plates were incubated further for overnight. Standard fluorescence was measured on a Fluostar Galaxy fluorometer (BMG LabTechnologies) at 544 nm excitation, 590 nm emission. Pentamidine and α-difluoromethylornithine (DFMO) were tested as standard (Table 1). The extracts that have shown more than 90 % inhibition of T. brucei growth in primary screening were subjected to secondary screening for dose–response analysis. Active extracts were screened at concentrations ranging from 10 – 0.4 μg/mL. IC50 and IC90 values were computed from dose response growth inhibition curve by XLfit version 5.2.2.
Table 1

In vitro antitrypanosomal activity of the most active plant extracts against Trypanosoma brucei

NPID

Sample name

Family

Common name

Plant part

IC50 (μg/mL)

IC90 (μg/mL)

81880

Alnus rubra

Betulaceae

Red alder

BK

0.94 ± 0.58

1.95 ± 0.17

81890

Boykinia major

Saxifragaceae

Large Boykinia

RT

2.82 ± 0.44

8.31 ± 1.50

81897

Juniperus communis

Cupressaceae

Juniper

LF-ST

2.40 ± 0.44

6.66 ± 2.13

81908

Chrysolepis chrysophylla

Fagaceae

Golden chinquapin

FL

2.89 ± 0.40

7.31 ± 1.57

81925

Rhododendron occidentale

Ericaceae

Western azalea

LF

2.87 ± 0.43

6.88 ± 1.16

81940

Arctostaphylos viscida

Ericaceae

Whiteleaf manzanita, sticky manzanita

LF

2.88 ± 0.21

5.96 ± 1.09

81953

Eriogonum umbellatum

Polygonaceae

Buckwheat

LF-ST

2.79 ± 0.34

6.25 ± 1.94

82438

Eriogonum fisciculatum

Polygonaceae

California or Eastern Mojave buckwheat

LF

2.68 ± 0.44

7.73 ± 2.33

82440

Rhus integrifolia

Anacardiaceae

Lemonade berry

LF

2.97 ± 0.01

4.41 ± 0.29

82453

Hoita macrostachya

Fabaceae

Large leatherroot

LF

0.48 ± 0.00

0.62 ± 0.00

82466

Lepechinia calycina

Lamiaceae

Pitcher sage; woodbalm

LF

2.50 ± 0.05

5.04 ± 0.12

82467

Ribes speciosum

Grossulariaceae

Fuchsia-flowered gooseberry

LF-ST-FL

2.95 ± 0.10

5.90 ± 0.08

82468

Salvia spathacea

Lamiaceae

Pitcher or hummingbird sage

ST

1.13 ± 0.78

3.46 ± 0.34

82484

Sabal minor

Arecaceae

Bush palmetto

FL

1.06 ± 0.44

2.07 ± 0.96

83334

Medinilla magnifica

Melastomataceae

Chandelier tree

FL-FR

2.25 ± 1.16

7.89 ± 2.48

83345

Eucalyptus citriodora

Myrtaceae

Lemon-scented gum

LF

2.91 ± 0.21

5.82 ± 0.04

83360

Acer rubrum

Sapindaceae

Red maple

LF

2.88 ± 0.50

7.45 ± 0.70

84470

Ligustrum sinense

Oleaceae

Privet

LF-FR

2.77 ± 0.40

4.41 ± 1.46

84516

Hamamelis virginiana

Hamamelidaceae

Witch hazel

ST

2.54 ± 0.53

4.65 ± 3.92

84686

Lyonia fruticosa

Ericaceae

Coastal plain staggerbush

ST

2.54 ± 0.71

4.65 ± 3.92

84709

Ribes montigenum

Grossulariaceae

Gooseberry-currant

ST

1.94 ± 0.67

7.39 ± 2.74

84712

Quercus alba

Fagaceae

White oak

BK

1.42 ± 0.30

7.53 ± 0.44

84715

Leea rubra

Vitaceae

West Indian holly, red leea

ST

1.62 ± 0.32

4.50 ± 1.04

84720

Coccoloba pubescens

Polygonaceae

Grandleaf seagrape

ST

0.83 ± 0.04

1.91 ± 0.16

84722

Rhus integrifolia

Anacardiaceae

Lemonade berry

ST

0.50 ± 0.10

1.07 ± 0.33

84738

Nuphar luteum

Nymphaeaceae

Water lilly

FR

0.42 ± 0.02

1.32 ± 0.11

131665

Difluoromethylornithine

   

5.07 ± 0.27

12.37 ± 0.96

103650

Pentamidine

   

0.002 ± 0.001

0.003 ± 0.001

(A complete list of plants screened is presented as supplement material –Additional file 1: Table S1 and Table S2) NPID- Natural Product Identification Details (accession number); Plant parts- BK- stem bark; LF- leaves; FL- flowers; ST- stem; FR- fruit; IC50 and IC90 values are mean ± SD

Cytotoxicity assay

The extracts were also tested for cytotoxicity against transformed human monocytic (THP1) cells. A 4 days’ old culture of THP1 cells in the experimental phase was diluted with RPMI medium to 2.5X 105 cells/mL. Phorbol 12-myristate 13-acetate (PMA) was added to the culture at 25 ng/mL concentration for transformation of the cells to adherent macrophages [13]. The PMA treated THP1 cell culture was dispensed in 96 well plates with 200 μl culture (2.5X 105 cells/mL) in each well and plates were incubated at 37 °C in 5 % CO2 incubator for overnight. Extracts were diluted in separate plates (Daughter plates) in RPMI medium. The medium in plates with THP1 cells was replaced with fresh medium. The diluted plant extracts were added to these plates. The plates were placed again in CO2 incubator at 37 °C, 5 % CO2 for 48 h. After 48 h 10 μl of alamar blue solution was added to each well and the plates were incubated further for overnight. Standard fluorescence was measured on a fluorometer at 544 nm ex, 590 nm em. Cytotoxicity screening was done for active extracts, which have shown more than 90 % inhibition in primary T. brucei screening. None of the T. brucei active plant extracts have shown more than 50 % inhibition on differentiated THP1 cells at 10 μg/mL concentration.

Results and discussion

The primary screening for T. brucei was done for extracts prepared from 522 plants collected from various parts of the North America (Additional file 1: Table S1). A significantly high number (150 extracts) of extracts showed >90 % inhibition of growth and proliferation of trypomastigote forms of T. brucei at 20 μg/mL. Secondary screening was done for active extracts at concentrations ranging from 10 – 0.4 μg/mL (Additional file 1: Table S2) and we identified ten plants extracts with potent antitrypanosomal activity with IC50 values <2 μg/mL (Table 1). Antitrypanosomal activity of these plants extracts was selective as none of these were significantly active against Leishmania donovani, Plasmodium falciparum (unpublished data) and transformed THP1 human macrophage cells (Additional file 1: Table S2). Plant extracts, those having IC50 less than 2 μg/mL in antitrypanosomal assay were Alnus rubra (0.94 μg/mL), Hoita macrostachya (0.48 μg/mL), Salvia spathacea (1.13 μg/mL), Sabal minor (1.06 μg/mL), Syzygium aqueum (1.84 μg/mL), Rubus odoratus (1.95 μg/mL), Ribes montigenum (1.94 μg/mL), Quercus alba (1.42 μg/mL), Leea rubra (1.62 μg/mL), Coccoloba pubescens (0.83 μg/mL), Rhus integrifolia (0.50 μg/mL), and Nuphar luteum (0.42 μg/mL). Eight additional plant extracts with IC50 in the range of 2.0- 2.5 μg/mL in antitrypanosomal assay were Juniperus communis (2.40 μg/mL), Lepechinia calycina (2.50 μg/mL), Salix caroliniana (2.24 μg/mL), Arceuthobium occidentale (2.47 μg/mL), Medinilla magnifica (2.25 μg/mL), Acer rubrum (2.06 μg/mL), Pinus aristata (2.42 μg/mL), Hypericum hypericoides (2.28 μg/mL) also represent new antitrypanosomal leads (Additional file 1: Table S2).

The active extracts were investigated for reported phytochemical and pharmacological activities. Alnus rubra, the Red alder, is a deciduous broadleaf tree native to western North America. It is the largest species of alder in North America and one of the largest in the world, reaching heights of 20–35 m. Native Americans have used various plant parts of Alnus rubra medicinally as a purgative, an emetic, for aching bones, headaches, coughs, biliousness, stomach problems, scrofula sores, tuberculosis, asthma, and eczema, and as a general panacea [14]. Antifungal and antibiotic activities have also been reported in Alnus rubra [15, 16]. Diarylheptenone 1-(3′,4’-dihydroxyphenyl)-7-(4''-hydroxyphenyl)-4-hepten-3-one and 1,7-bis(P-hydroxyphenyl)-4-hepten-3-one were isolated from Alnus rubra bark and their structures elucidated by spectrometric techniques [17]. A few minor diarylheptanoid glycosides namely, diarylheptanoid (S)-1,7-bis-(4-hydroxyphenyl)-heptan-3-one-5-O-beta-D-xylopyranoside, and two known compounds, 1,7-bis-(3,4-dihydroxyphenyl)-heptan-3-one-5-O-beta-D-glucopyranoside and platyphylloside were also isolated from Alnus rubra bark [18]. Alnus rubra extract is a novel antitrypanosomal lead. Hoita macrostachya is a species of legume known by the common name Large Leather Root. It is native to California and Baja California where it can be found in moist areas of a number of habitat types. This is a hairy, glandular perennial herb producing a tall, branching stem approaching two meters in maximum height. The potent antitrypanosomal activity reported herein is the first pharmacological activity reported in this plant. No phytochemical data are available on Hoita macrostachya. Therefore, this also represents a novel antitrypanosomal lead. Sabal minor (Arecaceae), commonly known as the Dwarf Palmetto or Bush palmetto, is one of about 14 species of Sabal palmetto palms. Native to the southeastern United States, ranging from Florida north to eastern North Carolina, and west to eastern Oklahoma and eastern Texas. Although it is mainly found in the southern states, it is one of the only palms that can withstand somewhat cooler temperatures, and has been cultivated in North and South Central Pennsylvania. This is the first report regarding antitrypanosomal activity in this plant. No phytochemical data are available on Sabal minor. Ribes montigenum plant commonly known as mountain gooseberry, alpine prickly currant, and gooseberry currant is native to Western North America (British Columbia to California to New Mexico). No previous phytochemical or pharmacological results are reported in this plant. Coccoloba pubescens (Grandleaf Seagrape; syn. C. grandifolia, also called “Eve’s Umbrella”) is a species of Coccoloba native to coastal regions of the Caribbean, on Antigua, Barbados, Barbuda, Dominica, Hispaniola, Martinique, Montserrat, and Puerto Rico. No phytochemical or pharmacological data are reported in this plant. Rhus integrifolia, also known as Lemonade Berry or Lemonade Sumac is a shrub to small tree. It is native to the Transverse and Peninsular Ranges and the South Coast regions of Southern California. This extends from Santa Barbara County and the Channel Islands to San Diego County and extending into north-central Pacific coastal Baja California and its offshore islands such as Cedros Island. This is the first report on any pharmacological activity in this plant. No phytochemical data are available on Rhus integrifolia. Nuphar lutea, the spatterdock, also known as yellow water-lily, cow lily, or yellow pond-lily, is an aquatic plant of the family Nymphaeaceae, native to Eurasia and North America. It grows in eutrophic freshwater beds, with its roots fixed into the ground and its leaves floating on the water’s surface. Strong inhibition of NFkappaB activity was found in extracts of leaf and rhizome from Nuphar lutea L. SM. (Nuphar). The inhibitory action was narrowed down to a mixture of thionupharidines and/or thionuphlutidines [19]. Antileishmanial activity has been reported in partially purified alkaloid fraction (NUP) of Nuphar lutea and dimeric sesquiterpene thioalkaloids were identified as the major constituents of the mixture [20]. The Nuphar lutea was identified as the most active antitrypanosomal plant extract with IC50 0.42 μg/mL Few additional plant extracts showed activity (IC50) in the range of 2–10 μg/mL. Antioxidant activity has been reported in extracts from Rhus hirta [21], a different species of Rhus integrifolia (T. brucei IC50- 2.97 μg/mL), Juniperus communis [22] (T. brucei IC50- 2.40 μg/mL) Sanguisorba officinalis [23] (T. brucei IC50 3.56 μg/mL), Syzygium malaccense [24] (T. brucei IC50 2.76 μg/mL) and Syzygium aqueum [25] (T. brucei IC50 1.84 μg/mL). Eucalyptus citriodora [26] (T. brucei IC50 3.34 μg/mL), Acer rubrum [27] (T. brucei IC50 2.07 μg/mL), Yucca glauca [28] (T. brucei IC50 3.56 μg/mL) plants have also been reported for anticancer activity. Antiviral activity is reported in Chamaecrista nictitans [29] (T. brucei IC50 5.76 μg/mL). Antimicrobial activity is reported in Liriodendron tulipifera [30] (T. brucei IC50 4.75 μg/mL) and Caesalpinia pulcherrima [31] (T. brucei IC50 4.76 μg/mL). Anthelminthic activity is reported in Quercus alba [32] (T. brucei IC50 1.42 μg/mL).

Conclusions

In conclusion, the in vitro screening of 522 extracts, prepared from plants collected from different parts of North America, against blood stage form of T. brucei has identified several plants extracts with potent antitrypanosomal activity and no cytotoxicity against THP1 cells. The active plants extracts namely, Alnus rubra, Hoita macrostachya, Salvia spathacea, Sabal minor, Ribes montigenum, Quercus alba, Leea rubra, Coccoloba pubescens, Rhus integrifolia and Nuphar luteum represent new antitrypanosomal leads. Most of the leadplant extracts have very limited phytochemical and pharmacological data available. Further follow up studies with these extracts are likely to provide novel compounds as potential antitrypanosomal drug leads.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not Applicable.

Availability of data and materials

All the data have been included in the supplementary data. Additional data, if required, can be made available on request. The plant material listed in manuscript can be shared, if available, on a mutually agreed material transfer agreements.

Abbreviations

DFMO: 

difluoromethyl ornithine

HAT: 

human african trypanosomiasis

IC50: 

concentration of extract producing 50 % inhibition in growth compared to controls

IC90: 

concentration of extract producing 90 % inhibition in growth compared to controls

MOBOT: 

Missouri Botanical Garden

NECT: 

nifurtomox/eflornithine combination

NPID: 

natural product identification details

PMA: 

phorbol 12-myristate 13-acetate

THP1: 

human acute monocytic leukemia cells

Declarations

Acknowledgments

The authors extend their appreciation to the National Center for Natural Products Research (NCNPR), Research Institute of Pharmaceutical Sciences and Scientific cooperative agreement with USDA- Agricultural Services. The Missouri Botanical Garden, St. Louis, Missouri (MOBOT) collected the plants reported in this paper through a cooperative scientific agreement with the NCNPR.

The authors are thankful to the staff of NCNPR repository for extraction and data-base support. The authors are also thankful to the MOBOT for plant material under a cooperative scientific agreement with the NCNPR.

Funding

This study has been supported by United States Department of Agriculture –Agricultural Research Services (USDA-ARS) Cooperative scientific agreement # 58-6408-2-0009.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi
(2)
Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi

References

  1. World Health O. Control and surveillance of human African trypanosomiasis. World Health Organ Tech Rep Ser. 2013;984:1–237.Google Scholar
  2. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375(9709):148–59.View ArticlePubMedGoogle Scholar
  3. Kennedy PG. Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness). Lancet Neurol. 2013;12(2):186–94.View ArticlePubMedGoogle Scholar
  4. Burri C. Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology. 2010;137(14):1987–94.View ArticlePubMedGoogle Scholar
  5. Lutje V, Seixas J, Kennedy A. Chemotherapy for second-stage human African trypanosomiasis. Cochrane Database Syst Rev. 2013;6:CD006201.PubMedGoogle Scholar
  6. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1998;881:I–VI. 1–114.Google Scholar
  7. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009;374(9683):56–64.View ArticlePubMedGoogle Scholar
  8. Gehrig S, Efferth T. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review). Int J Mol Med. 2008;22(4):411–9.PubMedGoogle Scholar
  9. Baker N, de Koning HP, Maser P, Horn D. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol. 2013;29(3):110–8.View ArticlePubMedGoogle Scholar
  10. Rollinger JM, Langer T, Stuppner H. Strategies for efficient lead structure discovery from natural products. Curr Med Chem. 2006;13(13):1491–507.View ArticlePubMedGoogle Scholar
  11. Sykes ML, Baell JB, Kaiser M, Chatelain E, Moawad SR, Ganame D, Ioset JR, Avery VM. Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign. PLoS Negl Trop Dis. 2012;6(11), e1896.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Cross GA, Kim HS, Wickstead B. Capturing the variant surface glycoprotein repertoire (the VSGnome) of Trypanosoma brucei Lister 427. Mol Biochem Parasitol. 2014;195(1):59–73.View ArticlePubMedGoogle Scholar
  13. Jain SK, Sahu R, Walker LA, Tekwani BL. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. J Vis Exp. 2012;70.Google Scholar
  14. Moerman DE. The medicinal flora of Native North America: an analysis. J Ethnopharmacol. 1991;31(1):1–42.View ArticlePubMedGoogle Scholar
  15. McCutcheon AR, Ellis SM, Hancock RE, Towers GH. Antibiotic screening of medicinal plants of the British Columbian native peoples. J Ethnopharmacol. 1992;37(3):213–23.View ArticlePubMedGoogle Scholar
  16. McCutcheon AR, Ellis SM, Hancock RE, Towers GH. Antifungal screening of medicinal plants of British Columbian native peoples. J Ethnopharmacol. 1994;44(3):157–69.View ArticlePubMedGoogle Scholar
  17. Chen J, Karchesy JJ, Gonzalez-Laredo RF. Phenolic diarylheptenones from Alnus rubra bark. Planta Med. 1998;64(1):74–5.View ArticlePubMedGoogle Scholar
  18. Chen J, Gonzalez-Laredo RF, Karchesy JJ. Minor diarylheptanoid glycosides of Alnus rubra bark. Phytochemistry. 2000;53(8):971–3.View ArticlePubMedGoogle Scholar
  19. Ozer J, Eisner N, Ostrozhenkova E, Bacher A, Eisenreich W, Benharroch D, Golan-Goldhirsh A, Gopas J. Nuphar lutea thioalkaloids inhibit the nuclear factor kappaB pathway, potentiate apoptosis and are synergistic with cisplatin and etoposide. Cancer Biol Ther. 2009;8(19):1860–8.View ArticlePubMedGoogle Scholar
  20. Ozer L, El-On J, Golan-Goldhirsh A, Gopas J. Leishmania major: anti-leishmanial activity of Nuphar lutea extract mediated by the activation of transcription factor NF-kappaB. Exp Parasitol. 2010;126(4):510–6.View ArticlePubMedGoogle Scholar
  21. Wu T, McCallum JL, Wang S, Liu R, Zhu H, Tsao R. Evaluation of antioxidant activities and chemical characterisation of staghorn sumac fruit (Rhus hirta L.). Food Chem. 2013;138(2–3):1333–40.View ArticlePubMedGoogle Scholar
  22. Yesilbag D, Cengiz SS, Cetin I, Meral Y, Biricik H. Influence of juniper (Juniperus communis) oil on growth performance and meat quality as a natural antioxidant in quail diets. Br Poult Sci. 2014;55(4):495–500.View ArticlePubMedGoogle Scholar
  23. Zhang S, Liu X, Zhang ZL, He L, Wang Z, Wang GS. Isolation and identification of the phenolic compounds from the roots of Sanguisorba officinalis L. and their antioxidant activities. Molecules. 2012;17(12):13917–22.View ArticlePubMedGoogle Scholar
  24. Savitha RC, Padmavathy S, Sundhararajan A. Invitro antioxidant activities on leaf extracts of syzygium malaccense (L.) merr and perry. Anc Sci Life. 2011;30(4):110–3.PubMedPubMed CentralGoogle Scholar
  25. Osman H, Rahim AA, Isa NM, Bakhir NM. Antioxidant activity and phenolic content of Paederia foetida and Syzygium aqueum. Molecules. 2009;14(3):970–8.View ArticlePubMedGoogle Scholar
  26. Shen KH, Chen ZT, Duh PD. Cytotoxic effect of eucalyptus citriodora resin on human hepatoma HepG2 cells. Am J Chin Med. 2012;40(2):399–413.View ArticlePubMedGoogle Scholar
  27. Gonzalez-Sarrias A, Li L, Seeram NP. Effects of maple (Acer) plant part extracts on proliferation, apoptosis and cell cycle arrest of human tumorigenic and non-tumorigenic colon cells. Phytother Res. 2012;26(7):995–1002.View ArticlePubMedGoogle Scholar
  28. Ali MS, Sharma GC, Asplund RO, Nevins MP, Garb S. Isolation of antitumor polysaccharide fractions from Yucca glauca Nutt. (Lilliaceae). Growth. 1978;42(2):213–23.PubMedGoogle Scholar
  29. Herrero Uribe L, Chaves Olarte E, Tamayo Castillo G. In vitro antiviral activity of Chamaecrista nictitans (Fabaceae) against herpes simplex virus: biological characterization of mechanisms of action. Rev Biol Trop. 2004;52(3):807–16.PubMedGoogle Scholar
  30. Hufford CD, Funderburk MJ, Morgan JM, Robertson LW. Two antimicrobial alkaloids from heartwood of Liriodendron tulipifera L. J Pharm Sci. 1975;64(5):789–92.View ArticlePubMedGoogle Scholar
  31. Sudhakar M, Rao Ch V, Rao PM, Raju DB, Venkateswarlu Y. Antimicrobial activity of Caesalpinia pulcherrima, Euphorbia hirta and Asystasia gangeticum. Fitoterapia. 2006;77(5):378–80.View ArticlePubMedGoogle Scholar
  32. Katiki LM, Ferreira JF, Gonzalez JM, Zajac AM, Lindsay DS, Chagas AC, Amarante AF. Anthelmintic effect of plant extracts containing condensed and hydrolyzable tannins on Caenorhabditis elegans, and their antioxidant capacity. Vet Parasitol. 2013;192(1–3):218–27.View ArticlePubMedGoogle Scholar

Copyright

© Jain et al. 2016

Advertisement